Canada Life’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.17M | Hold |
70,518
| – | – | ﹤0.01% | 1156 |
|
|
2026
Q1 | $1.53M | Sell |
70,518
-3,344
| -5% | -$72.2K | ﹤0.01% | 1237 |
|
|
2025
Q4 | $1.76M | Buy |
73,862
+14,610
| +25% | +$298K | ﹤0.01% | 1205 |
|
|
2025
Q3 | $789K | Hold |
59,252
| – | – | ﹤0.01% | 1502 |
|
|
2025
Q2 | $482K | Buy |
59,252
+7,102
| +14% | +$60.7K | ﹤0.01% | 1613 |
|
|
2025
Q1 | $410K | Hold |
52,150
| – | – | ﹤0.01% | 1645 |
|
|
2024
Q4 | $775K | Hold |
52,150
| – | – | ﹤0.01% | 1535 |
|
|
2024
Q3 | $798K | Sell |
52,150
-6,702
| -11% | -$106K | ﹤0.01% | 1570 |
|
|
2024
Q2 | $895K | Buy |
58,852
+12,426
| +27% | +$201K | ﹤0.01% | 1525 |
|
|
2024
Q1 | $876K | Hold |
46,426
| – | – | ﹤0.01% | 1533 |
|
|
2023
Q4 | $886K | Hold |
46,426
| – | – | ﹤0.01% | 1534 |
|
|
2023
Q3 | $834K | Buy |
46,426
+932
| +2% | +$18.7K | ﹤0.01% | 1547 |
|
|
2023
Q2 | $924K | Sell |
45,494
-3,239
| -7% | -$61.7K | ﹤0.01% | 1521 |
|
|
2023
Q1 | $888K | Sell |
48,733
-4,222
| -8% | -$80.7K | ﹤0.01% | 1545 |
|
|
2022
Q4 | $1.09M | Sell |
52,955
-3,798
| -7% | -$105K | ﹤0.01% | 1488 |
|
|
2022
Q3 | $1.48M | Buy |
56,753
+11,683
| +26% | +$309K | ﹤0.01% | 1320 |
|
|
2022
Q2 | $1.14M | Buy |
45,070
+43,254
| +2,382% | +$1.06M | ﹤0.01% | 1422 |
|
|
2022
Q1 | $61K | Sell |
1,816
-694
| -28% | -$23.3K | ﹤0.01% | 2110 |
|
|
2021
Q4 | $101K | Hold |
2,510
| – | – | ﹤0.01% | 2009 |
|
|
2021
Q3 | $88K | Hold |
2,510
| – | – | ﹤0.01% | 2084 |
|
|
2021
Q2 | $69K | Hold |
2,510
| – | – | ﹤0.01% | 2171 |
|
|
2021
Q1 | $70K | Sell |
2,510
-1,041
| -29% | -$36.2K | ﹤0.01% | 2191 |
|
|
2020
Q4 | $92K | Buy |
3,551
+1,871
| +111% | +$45.3K | ﹤0.01% | 2131 |
|
|
2020
Q3 | $29K | Hold |
1,680
| – | – | ﹤0.01% | 2337 |
|
|
2020
Q2 | $41K | Buy |
1,680
+1,252
| +293% | +$33.8K | ﹤0.01% | 2285 |
|
|
2020
Q1 | $6K | Hold |
428
| – | – | ﹤0.01% | 2563 |
|
|
2019
Q4 | $4K | Buy |
+428
| New | +$3.6K | ﹤0.01% | 2625 |
|
|
2019
Q3 | – | Sell |
-4,956
| Closed | -$39K | – | 2011 |
|
|
2019
Q2 | $39K | Hold |
4,956
| – | – | ﹤0.01% | 2502 |
|
|
2019
Q1 | $62K | Hold |
4,956
| – | – | ﹤0.01% | 2208 |
|
|
2018
Q4 | $51K | Buy |
+4,956
| New | +$57.9K | ﹤0.01% | 2369 |
|
Other funds holding RCUS
GS
SCM
WP
Canada Life's RCUS Position: Q2 2026 in Review
Canada Life held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 70,518 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1156.
Canada Life first reported a position in RCUS in Q4 2018 and has held it in 30 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.
- Canada Life held 70,518 shares of Arcus Biosciences worth $2.17M as of Q2 2026.
- Canada Life left its Arcus Biosciences share count unchanged in Q2 2026.
- Arcus Biosciences made up ﹤0.01% of Canada Life's portfolio in Q2 2026, its #1156 holding.
- Canada Life first reported a position in Arcus Biosciences in Q4 2018 and has held it in 30 quarters since.
- 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.
Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.